| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Hiroyoshi Takeuchi, Takefumi Suzuki, Hiroyuki Uchida, Shinichiro Nakajima, Kensuke Nomura, Toshiaki Kikuchi, Hiroshi Manki, Koichiro Watanabe, Haruo Kashim. A randomized, open-label comparison of 2 switching strategies to aripiprazole treatment in patients with schizophrenia: add-on, wait, and tapering of previous antipsychotics versus add-on and simultaneous tapering. Journal of clinical psychopharmacology. vol 28. issue 5. 2008-11-24. PMID:18794650. |
we conducted a randomized, 14-week, open-label trial to compare the following 2 switching strategies: (1) add-on of aripiprazole on a current regimen, wait for 4 weeks, and the tapering of prior antipsychotics and (2) add-on of aripiprazole and the simultaneous tapering of prior antipsychotics in patients with schizophrenia. |
2008-11-24 |
2023-08-12 |
human |
| David Taylor, Linda Hanssens, Jean-Yves Loze, Miranda Pans, Gilbert L'Italien, Ronald N Marcu. Preference of medicine and patient-reported quality of life in community-treated schizophrenic patients receiving aripiprazole vs standard of care: results from the STAR study. European psychiatry : the journal of the Association of European Psychiatrists. vol 23. issue 5. 2008-11-18. PMID:18423987. |
to evaluate quality of life and patient preference for schizophrenia treatment in a community based study comparing the use of aripiprazole to the standard of care (soc). |
2008-11-18 |
2023-08-12 |
Not clear |
| Robert L Findling, Adelaide Robb, Margaretta Nyilas, Robert A Forbes, Na Jin, Svetlana Ivanova, Ronald Marcus, Robert D McQuade, Taro Iwamoto, William H Carso. A multiple-center, randomized, double-blind, placebo-controlled study of oral aripiprazole for treatment of adolescents with schizophrenia. The American journal of psychiatry. vol 165. issue 11. 2008-11-18. PMID:18765484. |
a multiple-center, randomized, double-blind, placebo-controlled study of oral aripiprazole for treatment of adolescents with schizophrenia. |
2008-11-18 |
2023-08-12 |
Not clear |
| Robert L Findling, Adelaide Robb, Margaretta Nyilas, Robert A Forbes, Na Jin, Svetlana Ivanova, Ronald Marcus, Robert D McQuade, Taro Iwamoto, William H Carso. A multiple-center, randomized, double-blind, placebo-controlled study of oral aripiprazole for treatment of adolescents with schizophrenia. The American journal of psychiatry. vol 165. issue 11. 2008-11-18. PMID:18765484. |
aripiprazole is a dopamine partial agonist approved for use in adults for short- and long-term treatment of schizophrenia and bipolar disorder. |
2008-11-18 |
2023-08-12 |
Not clear |
| Robert L Findling, Adelaide Robb, Margaretta Nyilas, Robert A Forbes, Na Jin, Svetlana Ivanova, Ronald Marcus, Robert D McQuade, Taro Iwamoto, William H Carso. A multiple-center, randomized, double-blind, placebo-controlled study of oral aripiprazole for treatment of adolescents with schizophrenia. The American journal of psychiatry. vol 165. issue 11. 2008-11-18. PMID:18765484. |
this study was designed to examine the acute efficacy, safety, and tolerability of aripiprazole for adolescents with schizophrenia. |
2008-11-18 |
2023-08-12 |
Not clear |
| Jayanti Bhattacharjee, Hany George G El-Saye. Aripiprazole versus typical antipsychotic drugs for schizophrenia. The Cochrane database of systematic reviews. issue 3. 2008-10-15. PMID:18646161. |
aripiprazole versus typical antipsychotic drugs for schizophrenia. |
2008-10-15 |
2023-08-12 |
Not clear |
| Mark Sanford, Gillian M Keatin. Aripiprazole in adolescents with schizophrenia: profile report. CNS drugs. vol 22. issue 6. 2008-09-24. PMID:18484794. |
aripiprazole in adolescents with schizophrenia: profile report. |
2008-09-24 |
2023-08-12 |
Not clear |
| M-A Crocq, V Camus, B Millet, J Gliskman, J-M Azorin, M-O Krebs, F Limosin, J Costentin, J Dalér. [Clinical potentialities and perspectives for the use of aripiprazole in other disorders than its classical indications. A critical analysis of the recent literature]. L'Encephale. vol 34. issue 2. 2008-09-09. PMID:18597728. |
aripiprazole is indicated for the treatment of schizophrenia in europe and the united states, and for bipolar disorders in the latter. |
2008-09-09 |
2023-08-12 |
Not clear |
| John W Newcomer, Joao Alberto Campos, Ronald N Marcus, Christopher Breder, Robert M Berman, Wendy Kerselaers, Gilbert J L'italien, Marleen Nys, William H Carson, Robert D McQuad. A multicenter, randomized, double-blind study of the effects of aripiprazole in overweight subjects with schizophrenia or schizoaffective disorder switched from olanzapine. The Journal of clinical psychiatry. vol 69. issue 7. 2008-09-09. PMID:18605811. |
a multicenter, randomized, double-blind study of the effects of aripiprazole in overweight subjects with schizophrenia or schizoaffective disorder switched from olanzapine. |
2008-09-09 |
2023-08-12 |
human |
| John W Newcomer, Joao Alberto Campos, Ronald N Marcus, Christopher Breder, Robert M Berman, Wendy Kerselaers, Gilbert J L'italien, Marleen Nys, William H Carson, Robert D McQuad. A multicenter, randomized, double-blind study of the effects of aripiprazole in overweight subjects with schizophrenia or schizoaffective disorder switched from olanzapine. The Journal of clinical psychiatry. vol 69. issue 7. 2008-09-09. PMID:18605811. |
this multicenter, randomized, double-blind study compared the metabolic effects of aripiprazole versus olanzapine in overweight persons with schizophrenia or schizoaffective disorder who were previously on olanzapine treatment. |
2008-09-09 |
2023-08-12 |
human |
| Gerhard Gründer, Christine Fellows, Hildegard Janouschek, Tanja Veselinovic, Christian Boy, Anno Bröcheler, Katrin M Kirschbaum, Sandra Hellmann, Katja M Spreckelmeyer, Christoph Hiemke, Frank Rösch, Wolfgang M Schaefer, Ingo Vernaleke. Brain and plasma pharmacokinetics of aripiprazole in patients with schizophrenia: an [18F]fallypride PET study. The American journal of psychiatry. vol 165. issue 8. 2008-09-04. PMID:18381901. |
brain and plasma pharmacokinetics of aripiprazole in patients with schizophrenia: an [18f]fallypride pet study. |
2008-09-04 |
2023-08-12 |
Not clear |
| Gerhard Gründer, Christine Fellows, Hildegard Janouschek, Tanja Veselinovic, Christian Boy, Anno Bröcheler, Katrin M Kirschbaum, Sandra Hellmann, Katja M Spreckelmeyer, Christoph Hiemke, Frank Rösch, Wolfgang M Schaefer, Ingo Vernaleke. Brain and plasma pharmacokinetics of aripiprazole in patients with schizophrenia: an [18F]fallypride PET study. The American journal of psychiatry. vol 165. issue 8. 2008-09-04. PMID:18381901. |
in order to further characterize its extrastriatal and time-dependent binding characteristics, the authors conducted positron emission tomography (pet) studies with the d(2)/d(3) antagonist [(18)f]fallypride at varying time points after the last aripiprazole administration in patients with schizophrenia. |
2008-09-04 |
2023-08-12 |
Not clear |
| Jae Seung Chang, Yong Min Ahn, Hye Jean Park, Kyu Young Lee, Se Hyun Kim, Ung Gu Kang, Yong Sik Ki. Aripiprazole augmentation in clozapine-treated patients with refractory schizophrenia: an 8-week, randomized, double-blind, placebo-controlled trial. The Journal of clinical psychiatry. vol 69. issue 5. 2008-09-03. PMID:18370574. |
aripiprazole augmentation in clozapine-treated patients with refractory schizophrenia: an 8-week, randomized, double-blind, placebo-controlled trial. |
2008-09-03 |
2023-08-12 |
Not clear |
| Jae Seung Chang, Yong Min Ahn, Hye Jean Park, Kyu Young Lee, Se Hyun Kim, Ung Gu Kang, Yong Sik Ki. Aripiprazole augmentation in clozapine-treated patients with refractory schizophrenia: an 8-week, randomized, double-blind, placebo-controlled trial. The Journal of clinical psychiatry. vol 69. issue 5. 2008-09-03. PMID:18370574. |
this randomized, double-blind, placebo-controlled study evaluated the efficacy and safety of aripiprazole augmentation in clozapine-treated patients with refractory schizophrenia. |
2008-09-03 |
2023-08-12 |
Not clear |
| Lawrence Blonde, Hong J Kan, Elane M Gutterman, Gilbert J L'Italien, Myoung S Kim, Linda Hanssens, Robert D McQuad. Predicted risk of diabetes and coronary heart disease in patients with schizophrenia: aripiprazole versus standard of care. The Journal of clinical psychiatry. vol 69. issue 5. 2008-09-03. PMID:18435564. |
predicted risk of diabetes and coronary heart disease in patients with schizophrenia: aripiprazole versus standard of care. |
2008-09-03 |
2023-08-12 |
Not clear |
| Lawrence Blonde, Hong J Kan, Elane M Gutterman, Gilbert J L'Italien, Myoung S Kim, Linda Hanssens, Robert D McQuad. Predicted risk of diabetes and coronary heart disease in patients with schizophrenia: aripiprazole versus standard of care. The Journal of clinical psychiatry. vol 69. issue 5. 2008-09-03. PMID:18435564. |
in clinical trials, effects on metabolic parameters with aripiprazole are similar to those with placebo and superior to those with olanzapine, and the schizophrenia trial of aripiprazole (star) demonstrated comparable efficacy of aripiprazole versus standard of care (soc; physicians' selection of quetiapine, olanzapine, or risperidone). |
2008-09-03 |
2023-08-12 |
Not clear |
| Richard S E Keefe, Anil K Malhotra, Herbert Y Meltzer, John M Kane, Robert W Buchanan, Anita Murthy, Mindy Sovel, Chunming Li, Robert Goldma. Efficacy and safety of donepezil in patients with schizophrenia or schizoaffective disorder: significant placebo/practice effects in a 12-week, randomized, double-blind, placebo-controlled trial. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. vol 33. issue 6. 2008-08-07. PMID:17625502. |
in total, 250 patients (18-55 years) with schizophrenia or schizoaffective disorder who were clinically stabilized on risperidone, olanzapine, quetiapine, ziprasidone, or aripiprazole, alone or in combination, were enrolled at 38 outpatient psychiatric clinics in the united states. |
2008-08-07 |
2023-08-12 |
Not clear |
| F Limosin, J M Azorin, M O Krebs, B Millet, J Glikman, V Camus, M A Crocq, J Costentin, J Dalér. [Present data and treatment schedule of aripiprazole in the treatment of schizophrenia]. L'Encephale. vol 34. issue 1. 2008-07-15. PMID:18514155. |
[present data and treatment schedule of aripiprazole in the treatment of schizophrenia]. |
2008-07-15 |
2023-08-12 |
Not clear |
| F Limosin, J M Azorin, M O Krebs, B Millet, J Glikman, V Camus, M A Crocq, J Costentin, J Dalér. [Present data and treatment schedule of aripiprazole in the treatment of schizophrenia]. L'Encephale. vol 34. issue 1. 2008-07-15. PMID:18514155. |
five short-term efficacy studies, conducted on 1648 patients presenting with schizophrenia or acute relapse of schizoaffective disorders, demonstrated the greater efficacy of aripiprazole than the placebo and comparable efficacy to that of haloperidol and risperidone. |
2008-07-15 |
2023-08-12 |
Not clear |
| F Limosin, J M Azorin, M O Krebs, B Millet, J Glikman, V Camus, M A Crocq, J Costentin, J Dalér. [Present data and treatment schedule of aripiprazole in the treatment of schizophrenia]. L'Encephale. vol 34. issue 1. 2008-07-15. PMID:18514155. |
aripiprazole is effective on all the dimensions of schizophrenia: the positive and negative and depressive and anxious symptomatology. |
2008-07-15 |
2023-08-12 |
Not clear |